Literature DB >> 20709033

Plasminogen and plasmin in Alzheimer's disease.

Rachel Barker1, Seth Love, Patrick G Kehoe.   

Abstract

In Alzheimer's disease, abnormal accumulation of Aβ leads to neuronal death and impaired Aβ degradation may play an important role in this accumulation. Plasmin is the key active protease in the plasminogen system and is capable of cleaving Aβ. Here we investigate plasminogen mRNA levels, plasminogen and plasmin protein levels and plasmin activity levels in post-mortem AD and control brain tissue. Plasminogen and plasmin distribution in the human brain was demonstrated by immunoperoxidase staining. Plasminogen mRNA levels were measured in 20 AD, 20 control and 15 Vascular dementia (VaD) brains by real-time PCR (RT-PCR). In an expanded cohort of 38 AD and 38 control brains plasminogen and plasmin protein levels were measured by dot blot and Western blot, respectively, while plasmin activity levels were measured by fluorogenic assay. Plasminogen and plasmin were present mainly in the neurons. Plasminogen mRNA levels were unaltered in the AD or VaD groups compared to the controls. Plasminogen and plasmin protein levels were not significantly altered in AD compared to controls. Plasmin activity was reduced in AD but this did not reach statistical significance. In contrast to some studies these data do not support the involvement of plasmin in the abnormal accumulation of Aβ in AD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709033     DOI: 10.1016/j.brainres.2010.08.025

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

1.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

2.  Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Authors:  Kwang Soo Kim; Yu Ree Choi; Ji-Young Park; Jung-Ho Lee; Dong Kyu Kim; Seung-Jae Lee; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

3.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

4.  Plasmin system of Alzheimer's disease patients: CSF analysis.

Authors:  Alessandro Martorana; Giulia M Sancesario; Zaira Esposito; Marzia Nuccetelli; Roberto Sorge; Amanda Formosa; Vincenzo Dinallo; Giorgio Bernardi; Sergio Bernardini; Giuseppe Sancesario
Journal:  J Neural Transm (Vienna)       Date:  2012-03-14       Impact factor: 3.575

Review 5.  Hemostasis components in cerebral amyloid angiopathy and Alzheimer's disease.

Authors:  Nicole Ziliotto; Francesco Bernardi; Fabrizio Piazza
Journal:  Neurol Sci       Date:  2021-05-27       Impact factor: 3.307

Review 6.  One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina.

Authors:  Vivek Gupta; Veer B Gupta; Nitin Chitranshi; Sumudu Gangoda; Roshana Vander Wall; Mojdeh Abbasi; Mojtaba Golzan; Yogita Dheer; Tejal Shah; Alberto Avolio; Roger Chung; Ralph Martins; Stuart Graham
Journal:  Cell Mol Life Sci       Date:  2016-06-22       Impact factor: 9.261

7.  Neuroserpin up-regulation in the Alzheimer's disease brain is associated with elevated thyroid hormone receptor-β1 and HuD expression.

Authors:  Bobban Subhadra; Kristin Schaller; Nicholas W Seeds
Journal:  Neurochem Int       Date:  2013-09-11       Impact factor: 3.921

8.  Urokinase-Type Plasminogen Activator Protects Cerebral Cortical Neurons from Soluble Aβ-Induced Synaptic Damage.

Authors:  Ariel Diaz; Paola Merino; Ji-Dong Guo; Manuel A Yepes; Patrick McCann; Tapasya Katta; Elise M Tong; Enrique Torre; Srikant Rangaraju; Manuel Yepes
Journal:  J Neurosci       Date:  2020-04-24       Impact factor: 6.167

Review 9.  Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.

Authors:  Manuel Yepes; Yena Woo; Cynthia Martin-Jimenez
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

10.  Activators and inhibitors of the plasminogen system in Alzheimer's disease.

Authors:  Rachel Barker; Patrick G Kehoe; Seth Love
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.